Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-10-02
2010-10-05
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S144100, C424S152100
Reexamination Certificate
active
07807167
ABSTRACT:
A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
REFERENCES:
patent: 5260210 (1993-11-01), Rubin et al.
patent: 5716648 (1998-02-01), Halskov et al.
patent: 5730978 (1998-03-01), Wayner
patent: 5840299 (1998-11-01), Bendig et al.
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6033665 (2000-03-01), Yednock
patent: 6602885 (2003-08-01), Baroudy et al.
patent: 2001/0046496 (2001-11-01), Brettman et al.
patent: 2005/0215556 (2005-09-01), Karlik et al.
patent: 9-500617 (1997-01-01), None
patent: 9-508272 (1997-08-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/03252 (1991-03-01), None
patent: WO 92/15683 (1992-06-01), None
patent: WO 93/15764 (1993-08-01), None
patent: WO 94/16094 (1994-07-01), None
patent: WO 95/19790 (1995-01-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 97/18838 (1997-05-01), None
Panzara and Sandrock. Natalizumab Therapy in Patients with Multiple Sclerosis, 25thCongress of the European Committee for Treatment and Research in Multiple Sclerosis. Sep. 9-12, 2009, Dusseldorf, Germany.
O'Connor et al, Return of Disease Activity After Cessation of Natalizumab Therapy in Patients with Multiple Sclerosis. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Sep. 9-12, 2009, Dusseldorf, Germany. P793.
Zivadinov et al, Natalizumab (Tysabri) Promotes Remyelination in Patients with Multiple Sclerosis. A Voxel-Wise Magnetization Transfer Imaging Case-Control Study. Neurology 2009;72 (Suppl 3):P03.071, A140.
Polman et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar. 2;354(9):899-910.
Munscauer et al. Natalizumab Significantly increases the Cumulative Probability of Sustained Improvement in Physical Disability. World Congress on Treatmen and Research in Multiple Sclerosis, Sep. 17-20, 2008, Montreal Canada, P474.
Vito G. Sasseville et el., “Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/α4-62 1 Integrin Interactions”, American Journal of Pathology, 1994, pp. 27-40, vol. 144, No. 1, American Society for Investigative Pathology with the assistance of Stanford University Libraries' HighWire Press, Stanford, California, USA.
Marina Pretolani et al., “Antibody to Very Late Activation Antigen 4 Prevents Antigen-Induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways”, J. Exp. Med., 1994, pp. 795-805, vol. 180, No. 3, The Rockefeller University Press with the assistance of Stanford University Libraries' HighWire Press, Stanford, California, USA.
V.B. Weg et al., “A Monoclonal Antibody Recognizing Very Late Activation Antigen-4 Inhibits Eosinophil Accumulation In Vivo”. J. Exp. Med., 1993, pp. 561-566, vol. 177, No. 2. The Rockefeller University Press with the assistance of Stanford University Libraries' HighWire Press, Stanford, California, USA.
L.C. Paul et al., “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts”, Transplantation Proceedings, 1993, pp. 813-814, vol. 25, No. 1, Pt. 1, Elsevier Science, Oxford, United Kingdom.
Patricia L. Chisholm et al., “Monoclonal Antibodies to the Integrin α-4 Subunit Inhibit the Murine Contact Hypersensitivity Response”, Eur. J. Immunol., 1993, pp. 682-688, vol. 23, No. 3, VCH Verlagsgesellschaft mbH, Weinheim, Germany.
Daniel K. Podolsky et al., “Attenuation of Colitis in the Cotton-Top Tamarin by Anti-α4 Integrin Monoclonal Antibody”, J. Clin. Invest., 1993, pp. 372-380, vol. 92, No. 1, The American Society for Clinical Investigation, Inc. with the assistance of Stanford University Libraries' HighWire Press, Stanford, California, USA.
Kazuya Tsukamoto et al., “Administration of Monoclonal Antibodies Against Vascular Cell Adhesion Molecule-1/Very Late Antigen-4 Abrogates Predisposing Autoimmune Diabetes in NOD Mice”, Cellular Immunology, 1995, pp. 193-201, vol. 165, No. 2, Academic Press, Inc., Elsevier Science, Oxford, United Kingdom.
Myron I. Cybulsky et al., “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis”, Science, 1991, pp. 788-791, vol. 251, No. 4995, American Association for the Advancement of Science with the assistance of Stanford University Libraries' HighWire Press, Stanford, California, USA.
Cannella et al., “The adhesion Molecule and Cytokine Profile of Multiple Sclerosis Lesions,” Ann Neurol. 37: 424-435 (1995).
Dore-Duffy et al. inFrontiers in Cerebral Vascular Biology: Transport and its RegulationDreues and Betz (eds) Plenum N.Y. pp. 243-248 (1993).
Karussis et al., “Treatment of chronic-relapsing experimental autoimmune encephalomyletitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide,” PNAS 90: 6400-6404 (1993).
Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation,” Protein Engineering, vol. 4, No. 7, pp. 773-783 (1991).
Lisak et al., “Effect of treament with copolymer 1(cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE), ”J. Neurol. Sciences 62: 281-293 (1983).
Monshizadegan et al., “VLA-4-dependent adhesion activities of U937 cells and guinea peg bronchoalveolar lavage leukocytes,” Agents Actions 39, pp. C177-C179 (1993).
Racke et al., “Long-term treatment of chronic relapsing experimental allergic encephalomyletits by transforming growth factor-β2,” J. Neuroimmunol. 46: 175-184 (1993).
Teitelbaum et al., “Synthetic copolymer 1 inhibits human t-cell lines specific for myelin basic protein, ”PNAS 89: 137-141 (1992).
Washington et al., “Expression of Immunologically Relevant Endothelial Cell Activation Antigens on Isolated Central Nervous System Microvessels from Patients with Multiple Sclerosis, ”Ann Neurol 35: 89-97 (1994).
Weiner et al., “Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis,” Science 259: 1321-1324 (1993).
Yednock et al., “Prevention of experimental autoimmune encephalomyletitis by antibodies against α4β1 integrin,” Letters to Nature, vol. 3546, pp. 63-66 (1991).
James S. Grober et al., “Monocyte-Endothelial Adhesion in Chronic Rheumatoid Arthritis,” J. Clin. Invest. vol. 91, pp. 2609-2619 91993).
S. Jalkanen et al., “A Novel Endothelial Cell Molecule Mediating Lymphocyte Binding in Humans,” Behring Inst. Mitt., No. 92, pp. 36-43 (1993).
C. Fischer et al., Lymphocyte-Endothelial Interactions Inflamed Synovia: Involvement of Several Adhesion Molecules and Integrin Epitopes, Scand. J. Immunol. vol. 38, pp. 158-166, (1993).
Marko Salmi et al., “Dual Binding Capacity of Mucosal Immunoblasts to Mucosal and Synovial Endothelium in Humans: Dissection of the Molecular Mechanisms,” J. Exp. Med., vol. 181, pp. 137-149 (1995).
Bernhard Holzmann et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α,” Cell vol. 56, pp. 37-46 (1989).
Thomas B. Issekutz, “Inhibition of in Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody,” The Journal of Immunology vol. 147(12) pp. 4178-4184 (1991).
Andrew C. Issekutz et al., “Monocyte Migration to Arthritis in the Rat Utilizes both CD11/CD18 and Ver
Taylor Julie
Yednock Theodore A.
Crowell & Moring LLP
Elan Pharmaceuticals Inc.
Haddad Maher M
LandOfFree
Administration of agents for the treatment of inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of agents for the treatment of inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of agents for the treatment of inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228363